Verve Therapeutics in the spotlight

Assessing $VERV's CRISPR gene-editing technology for treating heart disease

As someone who was personally interviewed by Dr. Sekar Kathiresan (CEO of $VERV) for a computational biology leadership position at Verve Therapeutics, I have tremendous respect for the company’s research, its co-founders and CEO, and overall vision for a “one and done treatment” for treating heterozygous familial hypercholesterolemia (i.e., extremely e…